Claims for Patent: 6,677,326
✉ Email this page to a colleague
Summary for Patent: 6,677,326
| Title: | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| Abstract: | The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis. |
| Inventor(s): | Bardsley; Hazel Judith (Cambridge, GB), Bannister; Robin Mark (Essex, GB), Gilbert; Julian Clive (Essex, GB) |
| Assignee: | Arakis, Ltd. (GB) |
| Application Number: | 10/263,044 |
| Patent Claims: |
1. A unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid.
2. The formulation according to claim 1, which comprises at least 0.25 mg of prednisolone or said equivalent. 3. The formulation according to claim 2, which comprises 0.5 to 2 mg of prednisolone or said equivalent. 4. The formulation according to claim 3, which comprises 1 to 1.25 mg of prednisolone or said equivalent. 5. The formulation according to claim 1, adapted to release at least 90% by weight of prednisolone or said equivalent 2 to 8 hours after administration. 6. The formulation according to claim 1, wherein said corticosteroid is a glucocorticoid. 7. The formulation according to claim 1, wherein said corticosteroid is selected from the group consisting of prednisone, budesonide, methylprednisolone, fluticasone, betamethasone, and deflazacort. 8. The formulation according to claim 7, wherein said corticosteroid is prednisone. 9. A method for the treatment of a patient suffering from a condition selected from the group consisting of asthma, inflammatory bowel disease, psoriasis, psoriatic arthritis, polymyalgia rheumatica, chronic obstructive pulmonary disease, and rheumatoid arthritis and other polyarthropathies, which comprises administering to the patient a unit dosage formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. 10. The method according to claim 9, wherein the formulation comprises at least 0.25 mg of prednisolone or said equivalent. 11. The method according to claim 10, wherein the formulation comprises 0.5 to 2 mg of the prednisolone or said equivalent. 12. The method according to claim 11, wherein the formulation comprises 1 to 1.25 mg of the prednisolone or said equivalent. 13. The method according to claim 9, wherein the formulation is adapted to release at least 90% by weight of the prednisolone or said equivalent 2 to 8 hours after administration. 14. The method according to claim 9, wherein said corticosteroid is a glucocorticoid. 15. The method according to claim 9, wherein said corticosteroid is selected from the group consisting of prednisone, budesonide, methylprednisolone, flutacasone, betamethasone, and deflazacort. 16. The method according to claim 15, wherein said corticosteroid is prednisone. 17. The method according to claim 8, wherein said corticosteroid is administered between midnight and 6 a.m. |
